XML 94 R91.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Commitments and contingencies - Narrative (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
Apr. 20, 2017 | May 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Aug. 23, 2018 | Jun. 30, 2016
Other contingencies |  |  |  |  |  |  |
Useful life |  |  | 7 years |  |  |  |
Purchase obligation |  |  | $ 6,900 |  |  |  |
Amortization of acquired intangible asset |  |  | 27,650 | $ 22,877 | $ 15,380 |  |
Akcea |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Upfront licensing fee |  | $ 6,000 |  | 12,000 |  |  |
Milestone, potential achievements, regulatory approval |  |  | 4,000 |  |  |  |
Collaborative Arrangement | Wellcome trust limited |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Development milestone payment obligations |  |  | $ 22,400 |  |  |  | $ 800
Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Development milestone payment obligations | $ 50,000 |  |  |  |  |  |
Non-collaborative Arrangement Transactions | Akcea |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Useful life |  |  | 10 years |  |  |  |
Milestone, potential achievements, regulatory approval |  | $ 6,000 | $ 4,000 |  |  |  |
Emflaza asset acquisition |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Emflaza rights | $ 148,373 |  |  |  |  |  |
Milestone, potential achievements, regulatory approval |  |  | 27,100 | $ 14,400 |  |  |
Marathon Pharmaceuticals, LLC |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Development milestone payment obligations |  |  | 11,400 |  |  |  |
Agilis |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Development milestone payment obligations |  |  | 40,000 |  |  | $ 40,000 |
Agilis | Non-collaborative Arrangement Transactions |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Development milestone payment obligations |  |  | 40,000 |  |  | $ 40,000 |
Maximum | Akcea |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Milestone, potential achievements, regulatory approval |  |  | 4,000 |  |  |  |
Maximum | Agilis |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Development milestone payment obligations |  |  | 60,000 |  |  |  |
Priority review voucher amount |  |  | 535,000 |  |  |  |
Net sales milestones |  |  | $ 150,000 |  |  |  |
Percentage of annual net sales |  |  | 6.00% |  |  |  |
Maximum | BioElectron |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Development milestone payment obligations |  |  | $ 200,000 |  |  |  |
Minimum | Agilis |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Percentage of annual net sales |  |  | 2.00% |  |  |  |
Intellectual Property |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Accumulated amortization |  |  | $ 65,900 |  |  |  |
Intellectual Property | Marathon Pharmaceuticals, LLC |  |  |  |  |  |  |
Other contingencies |  |  |  |  |  |  |
Useful life | 7 years |  |  |  |  |  |

X
- Definition Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
Namespace Prefix: | ptct_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements. + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligations
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payment which the entity is obliged to pay upon regulatory approval + References No definition available. + Details
Name: | ptct_MilestonePotentialAchievementsRegulatoryApproval
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront Licensing Fee + References No definition available. + Details
Name: | ptct_UpfrontLicensingFee
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + References No definition available. + Details
Name: | us-gaap_PurchaseObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_AkceaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_EmflazaassetacquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_MarathonPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |